Type 1 interferon activation in systemic sclerosis: a biomarker, a target or the culprit. Issue 6 (16th November 2022)

• Record Type: Journal Article
• Authors: Kakkar, Vishal; Assassi, Shervin; Allanore, Yannick; Kuwana, Masataka; Denton, Christopher P.; Khanna, Dinesh; Del Galdo, Francesco
• Is Part Of: Current opinion in rheumatology. Volume 34:Issue 6(2022)
• Page Start: 357
• Page End: 364
• Publication Date: 2022-11-16
• Subjects: interferon regulatory factors -- plasmacytoid dendritic cells -- systemic sclerosis -- Toll-like receptors -- type 1 interferon; Rheumatology -- Periodicals; Arthritis -- Periodicals; Review Literature -- Periodicals; Rheumatic Diseases -- Periodicals; 616.723
• DOI: 10.1097/BOR.0000000000000907
• Languages: English
• ISSNs: 1040-8711

Abstract

Abstract : Purpose of review: Activation of the type 1 interferon (T1 IFN) pathway has been implicated in the pathogenesis of systemic sclerosis (SSc) by an increasing number of studies, most of which share key findings with similar studies in systemic lupus erythematosus (SLE). Here we will focus on the evidence for T1 IFN activation and dysregulation in SSc, and the rationale behind targeting the pathway going forward. Recent findings: An increased expression and activation of T1 IFN-regulated genes has been shown to be present in a significant proportion of SSc patients. TI IFN activation markers have been found to predict and correlate with response to immunosuppressive treatment as well as severity of organ involvement. As inhibition of the IFN-α receptor has been proven to be effective in active SLE, benefit may be seen in targeting the IFN pathway in SSc. Summary: The role played by T1 IFN and its regulatory genes in SSc is becoming increasingly evident and strikingly similar to the role observed in SLE. This observation, together with the benefit of type 1 IFN targeting in SLE, supports the notion of a potential therapeutic benefit in targeting T1 IFN in SSc.